aInOStICS

The Sixth Sense in Medical Diagnostics

AINOSTICS is an award winning artificial intelligence company from the UK, commercialising over two decades of world-leading research into the diagnosis of neurological disorders by our founding team and globally recognised scientific advisors.

Our technology represents a breakthrough that would provide an automated, extensible and personalised healthcare platform for assisting the clinical diagnosis of tissue modifying diseases using multi-modal clinical imaging and non-imaging data. We aim for our solutions to become a routine part of clinical practice and drug development.

About

Imaging...and more

At AINOSTICS we are working to identify the earliest biological signs of some of our society’s most devastating diseases, such as Alzheimer’s disease, Multiple Sclerosis, Stroke and brain tumours, providing the best chance of success for potential preventions and treatments.

Through connecting basic science with medical expertise, we aim to address the unmet needs of the demanding clinical environment, augmenting human knowledge with objectivity and reliability.

low-poly-brain-3d-model-low-poly-max-obj

Many solutions. One vision

We combine the most exciting medical imaging innovations with the best of artificial intelligence solutions to unlock the future of personalised diagnosis, prognosis, and therapy monitoring and planning.

We are constantly developing algorithms to improve workflow across the entire clinical imaging pathway, utilising the state-of-the-art in areas such as image acquisition, quality control, data encoding, modelling and inference, with the goal of offering a comprehensive pipeline that will empower clinicians to deliver faster and better care, ultimately improving patient outcomes.

Our Past

2019

With the aim of commercialisation a back catalogue of groundbreaking technologies resulting from over two decades of research in the fields of imaging, computational modelling and artificial intelligence, AINOSTICS started its operations in the UK.

By the end of 2019, the innovation we were bringing to the field was already being recognised, with the Company picking up various prestigious awards, such as being selected as the top medical AI company in the Hangzhou Innovation and Entrepreneurship Competition 2019, one of the biggest innovation competitions in China.

Our Future

2020 - 2024

2020 was truly a leap year at AINOSTICS. We secured approximately $2.5 million to accelerate our product development and validation.

In 2021 we extensively verified our methodologies using thousands of datasets from patients and healthy individuals, further exemplifying IQ's unique capabilities.

In 2022 we secured approximately $3.5 million in additional funding to accelerate our clinical validation studies. and our flagship product, BR[AI]N®, became the first solution to be granted FDA Breakthrough Device status for the ability to accurately predict conversion to Alzheimer's disease using structural MRI scans only!

In 2023 we expanded our product pipeline. We also established key partnerships with clinical and Pharma collaborators to realise our go-to-market strategy.

In 2024 we secured our first major contract to provide our data analytics and outcome prognostic services in a global dementia clinical trial study.

2025

In 2024, we aim to obtain regulatory approval in additional territories and deploy our clinical and Pharma solutions at a number of sites globally, so stay tuned!